THE DEAL, AT A GLANCE
From the announcementTypewriter Therapeutics
01Gene therapy development What it doesTypewriter Therapeutics is developing a non-viral gene therapy delivery platform.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedTypewriter Therapeutics raised $56M Series A, announced 2026-09-03From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersTypewriter Therapeutics' $56M Series A signals continued capital availability for Healthcare & Life Sciences platforms, with the round positioned near the median of…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Typewriter Therapeutics · Financing Record
Explore source-linked visual explanations for Typewriter Therapeutics. Unsupported claims are withheld while source review continues.
Record 11597 · Recorded date: 2026-09-03
Explore company records →